Top Suppliers:I want be here
Related CAS#:
67400-17-3 78214-33-2
7821-33-2 38243-03-7
68406-26-8 511-20-6
62025-49-4 14197-60-5
112246-15-8 87741-78-4
923721-63-5 1158522-08-7
940364-43-2 134104-43-1
131615-57-1 951-73-5
6906-52-1 930439-75-1
1013755-83-3 919040-95-2

78214-33-2

78214-33-2 structure
78214-33-2 structure
  • Name: 20(S)-Ginsenoside Rh2
  • Chemical Name: (20S)-ginsenoside Rh2
  • CAS Number: 78214-33-2
  • Molecular Formula: C36H62O8
  • Molecular Weight: 622.873
  • Catalog: Biochemical Natural product
  • Create Date: 2018-02-06 08:00:00
  • Modify Date: 2024-01-02 17:16:43
  • Ginsenoside Rh2 is isolated from the root of Ginseng. Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
Name (20S)-ginsenoside Rh2
Synonyms (3β,12β)-12,20-Dihydroxydammar-24-en-3-yl β-D-glucopyranoside
β-D-Glucopyranoside, (3β,12β)-12,20-dihydroxydammar-24-en-3-yl
ginenoside Rh2
MFCD00800712
(3β,12β)-12,20-Dihydroxydammar-24-en-3-yl-β-D-glucopyranoside
dihydroxydammar-24-en-3-yl
β-D-Glucopyranoside, (3α,5ξ,9ξ,12α,13α,14β)-12,20-dihydroxydammar-24-en-3-yl
(2R,3R,4S,5S,6R)-2-[[(3R,8R,10R,12S,13S,14S,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
Ginsenoside Rh2
GinsenosideRh2
(3α,5ξ,9ξ,12α,13α,14β)-12,20-Dihydroxydammar-24-en-3-yl β-D-glucopyranoside
Ginsenoside Rh2, 20(S)-
Description Ginsenoside Rh2 is isolated from the root of Ginseng. Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
Related Catalog
Target

Caspase-8

Caspase-9

Apoptosis

In Vitro Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC50 value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC50 values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC50 value of 7.85 μg/mL, 3-fold higher than HeLa cells[1].
In Vivo A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P<0.05). The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent (P<0.05)[2].
Kinase Assay HeLa, SK-HEP-1, SW480, and PC-3 cells are treated with Ginsenoside Rh2 (7.5 μg/mL) in serum free media for indicated time periods and then are harvested. Fifty micrograms of cell lysates are incubated with 200 nM Ac-DEVD-AFC (for caspase-3), Ac-IETD-AFC (for caspase-8), and Ac-LEHD-AFC (for caspase-9) in a reaction buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM DTT, 0.1% CHAPS, and 10% sucrose at 37°C for 1 h. The reaction is monitored by fluorescence emission at 535 nm and excitation at 405 nm[1].
Cell Assay Determination of cell viability is performed by using MTT assay, which is used to calculate the growth inhibition induced by increasing concentrations of drug. Briefly, exponentially growing HeLa, SK-HEP-1, SW480, and PC-3 cells are seeded into a 96-well plate at 1×104 cells/well in triplicate. After incubation for 24 h, cells are treated with increasing concentration of Ginsenoside Rh2 (1, 2.5, 5, 7.5 and 10 μg/mL) in serum free media for 48 h. At the end of treatment, 20 μL of MTT (5 mg/mL) is added to each well and incubated for an additional 4 h. The formazan grains formed by viable cells are solubilized with DMSO, and the color intensity is measured at 550 nm with an ELISA reader[1].
Animal Admin Mice[2] Male C57BL6 mice (3-4 weeks old) are randomly arranged into 4 groups of 80 mice: Tumor group, G-L group, G-H group and Control group. G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection. For the tumor group, G-L group and G-H group, the B16-F10 cell line is injected into the mice. These 3 groups become tumor bearing groups. For the control group, the same volume of PBS is injected instead. Ginsenoside Rh2 is injected into the left back of mice in the G-L and G-H groups. The dose for the G-H group is 0.5 mg/kg or 0.2 mg/kg for G-L group, every 2 days after day 5. PBS is injected in the tumor and control groups at the same time points.
References

[1]. Guo XX, et al. p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell. 2014 Mar;5(3):224-34.

[2]. Wang M, et al. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett. 2017 Feb;13(2):681-685.
Density 1.2±0.1 g/cm3
Boiling Point 726.4±60.0 °C at 760 mmHg
Molecular Formula C36H62O8
Molecular Weight 622.873
Flash Point 393.1±32.9 °C
Exact Mass 622.444458
PSA 139.84000
LogP 5.62
Vapour Pressure 0.0±5.4 mmHg at 25°C
Index of Refraction 1.572
Storage condition 2-8°C
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H302
Hazard Codes Xi
Risk Phrases R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S26-S36/37/39
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS LZ5776539

Chemsrc provides CAS#:78214-33-2 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 78214-33-2 | Chemsrc address: https://m.chemsrc.com/en/baike/894762.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved